Cortex Pharmaceuticals Inc. — Department of Health and Human Services SBIR Phase I: <p>Using plethysmographic measurements in various groups of rats, the proposed studies wil
Cortex Pharmaceuticals Inc. — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $148,583
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- NAICS
- —
- Place of performance
- NJ
- Period
- —
Description
<p>Using plethysmographic measurements in various groups of rats, the proposed studies will determine the potency, latency to onset and duration of action of CX1942 when adminisstered either prior to, simultaneously with or subsequent to administration of either an opiate (morphine or fentanyl), a benzodiazepine (diazeman or alprazolam) in combination with an opiate or a benzodiazepine in combination with ethanol. PUBLIC HEALTH RELEVANCE</p>